C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H2 2016', provides in depth analysis on C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted pipeline therapeutics. 

The report provides comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Overview 8
Therapeutics Development 9
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Stage of Development 9
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Therapy Area 10
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Indication 11
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Companies 14
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Universities/Institutes 17
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development 26
American Gene Technologies International Inc. 26
Calimmune, Inc. 27
ChemoCentryx, Inc. 28
Cytodyn Inc. 29
GlaxoSmithKline Plc 30
Pharis Biotec GmbH 31
Tobira Therapeutics, Inc. 32
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles 33
(cenicriviroc mesylate + efavirenz + lamivudine) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
(cenicriviroc mesylate + evogliptin) - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
(cenicriviroc mesylate + lamivudine) - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
AG-1105 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
CAL-21 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CAL-MGMT - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
CAL-X - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CCL-14 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
cenicriviroc mesylate - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
DS-001 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
DS-004 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
DS-005 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
GSK-214096 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
PRO-140 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
RAP-103 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
VIP - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Projects 65
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products 68
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Featured News & Press Releases 69
Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting 69
Oct 13, 2016: bioMONTR Labs to Provide Testing Services for CytoDyn PRO 140 Clinical Trials 70
Oct 06, 2016: CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After Positive FDA Meeting 70
Oct 03, 2016: Tobira Therapeutics Announces Presentations Related to Cenicriviroc's Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting 70
Sep 12, 2016: Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin 71
Sep 07, 2016: Tobira Therapeutics Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee 72
Aug 23, 2016: Patients Approach Two Years of Complete HIV Viral Load Suppression in Phase 2b PRO 140 Monotherapy Extension Study 72
Jul 26, 2016: First Patient Enrolled Under Newly Modified Protocol in CytoDyn's Phase 3 PRO 140 Combination Study in HIV 73
Jul 25, 2016: Tobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year 74
Jul 21, 2016: CytoDyn Submits Orphan Drug Application to FDA for Pretreatment With PRO 140 of Treatment-Naive HIV Patients 75
Jul 19, 2016: CytoDyn Submits Protocol for Phase 2b Trial for Treatment Naive HIV Patients 76
Jun 27, 2016: Tobira's Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH 77
Jun 22, 2016: ASM Microbe 2016 Presentation of Clinical Results From CytoDyn's Phase 2b Monotherapy Extension Study Now Available 77
Jun 17, 2016: CytoDyn's PRO 140 Phase 2b HIV Monotherapy Trial Findings to be Presented at ASM Microbe 2016 Conference on June 20 78
Jun 16, 2016: Tobira's Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Assessment by Monotherapy/Combination Products, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Pipeline by American Gene Technologies International Inc., H2 2016 26
Pipeline by Calimmune, Inc., H2 2016 27
Pipeline by ChemoCentryx, Inc., H2 2016 28
Pipeline by Cytodyn Inc., H2 2016 29
Pipeline by GlaxoSmithKline Plc, H2 2016 30
Pipeline by Pharis Biotec GmbH, H2 2016 31
Pipeline by Tobira Therapeutics, Inc., H2 2016 32
Dormant Projects, H2 2016 65
Dormant Projects (Contd..1), H2 2016 66
Dormant Projects (Contd..2), H2 2016 67
Discontinued Products, H2 2016 68